GlassScriptPhysician profile
Zachary M Boylan
NPI 1356670509
$4,166.92
in general payments reported to CMS, 2019-2025
29 companies · $507 in 2025
The $507 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $691 · 2020: $476 · 2021: $1,078 · 2022: $659 · 2023: $540 · 2024: $217 · 2025: $507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,264.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $845.71 | 2020-2023 | Ubrelvy, Qulipta, Vraylar |
| Pfizer INC. | $558.51 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $397.49 | 2019-2022 | |
| Novo Nordisk INC | $317.45 | 2019-2022 | |
| Amarin Pharma, INC. | $216.81 | 2019-2022 | |
| Astellas Pharma US INC | $184.23 | 2019-2025 | Veozah |
| Amgen INC. | $181.93 | 2019-2025 | Krystexxa |
| Allergan, INC. | $179.99 | 2019-2020 | |
| Eisai INC. | $158.54 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $155.39 | 2020-2021 | |
| Dexcom, INC. | $147.31 | 2021-2025 | Dexcom G6 Transmitter |
| Merit Medical Systems INC | $124.00 | 2025 | Esophyx |
| Glaxosmithkline, LLC. | $114.35 | 2021-2023 | Shingrix, Fluarix Quadrivalent, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.87 | 2019-2024 | Synjardy, Jardiance |
| Astrazeneca Pharmaceuticals LP | $80.08 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $77.78 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $60.30 | 2019-2021 | |
| Upsher-Smith Laboratories LLC | $49.96 | 2020 | |
| Shire North American Group INC | $27.08 | 2019 | |
| Sunovion Pharmaceuticals INC. | $27.06 | 2021 | |
| Lilly USA, LLC | $25.01 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $24.70 | 2019-2021 | |
| Siemens Medical Solutions USA, INC. | $23.52 | 2025 | Immulite 1000 Immunoassay System |
| Biohaven Pharmaceutical Holding Company LTD. | $21.78 | 2022 | |
| Gilead Sciences, INC. | $20.99 | 2019 | |
| Sanofi-Aventis U.S. LLC | $17.02 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.93 | 2021 | |
| Novartis Pharmaceuticals Corporation | $16.72 | 2019 | |
| Corcept Therapeutics | $14.41 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zachary Boylan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.